Health ❯ Healthcare ❯ Pharmaceuticals ❯ Weight Loss

GLP-1 Drugs

Kailera Leaps 62% in Nasdaq Debut After $625 Million IPO

The strong debut signals renewed investor interest in obesity drugs.

DNA Links Found for Who Loses Weight and Who Gets Sick on GLP-1 Drugs

FDA Clears Eli Lilly’s Foundayo Oral GLP-1 for Weight Loss, With U.S. Launch Set for April 6

FDA Clears Lilly’s Foundayo Pill, Escalating GLP-1 Weight-Loss Rivalry

India Tightens Oversight of GLP-1 Drugs as Semaglutide Generics Proliferate

India Braces for 50+ Semaglutide Generics as Patent Expires Friday

Novo’s CagriSema Falls Short of Lilly’s Tirzepatide in 84-Week Head‑to‑Head Trial

Serena Williams’ Super Bowl Ro Ad Promotes GLP-1 Weight Loss, Draws Backlash

Hims & Hers Halts $49 Compounded Wegovy Pill as FDA Tightens GLP-1 Rules

Hims Launches $49 Compounded Wegovy-Style Pill as Novo Vows Legal Action

Jefferies Model Links GLP-1 Weight Loss Use to $580 Million in Annual Airline Fuel Savings

New Evidence Flags Rapid Weight Regain After Stopping GLP-1 Drugs

BMJ Review Flags Rapid Weight Regain After GLP‑1 Stop as UK Approves Higher‑Dose Wegovy

Novo Nordisk Launches Wegovy Weight‑Loss Pill in U.S. at $149 Starter Price

FDA Approves First Oral GLP-1 for Obesity as Novo’s Wegovy Pill Sets January U.S. Launch

FDA Approves Wegovy Weight-Loss Pill as First Oral GLP-1 for Obesity

Lilly’s Daily Obesity Pill Sustains Weight Loss After Switch From Wegovy or Zepbound

WHO Endorses GLP‑1s for Obesity as Australia Adds Class‑Wide Mental Health Warning

Stopping GLP-1 Weight-Loss Drugs Before Pregnancy Linked to Higher Gestational Risks, Study Finds

U.S. Strikes Price-Cut Deals With Novo Nordisk and Eli Lilly for GLP‑1s, With Medicare Pilot in 2026